Organon & Co. (NYSE:OGN) Position Increased by Private Management Group Inc.

Private Management Group Inc. grew its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 11.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,119,288 shares of the company's stock after acquiring an additional 225,420 shares during the quarter. Organon & Co. comprises about 1.1% of Private Management Group Inc.'s investment portfolio, making the stock its 23rd largest holding. Private Management Group Inc. owned about 0.82% of Organon & Co. worth $31,620,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of OGN. Squarepoint Ops LLC acquired a new position in Organon & Co. during the 2nd quarter valued at about $671,000. Cetera Investment Advisers boosted its position in shares of Organon & Co. by 2.4% during the second quarter. Cetera Investment Advisers now owns 58,599 shares of the company's stock worth $1,213,000 after buying an additional 1,378 shares during the period. SG Americas Securities LLC grew its holdings in Organon & Co. by 161.1% in the 3rd quarter. SG Americas Securities LLC now owns 22,689 shares of the company's stock worth $434,000 after buying an additional 14,000 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Organon & Co. by 6.6% in the 3rd quarter. Handelsbanken Fonder AB now owns 68,250 shares of the company's stock worth $1,306,000 after buying an additional 4,250 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Organon & Co. by 57.6% in the 3rd quarter. GAMMA Investing LLC now owns 6,362 shares of the company's stock valued at $122,000 after acquiring an additional 2,326 shares during the period. Institutional investors own 77.43% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, TD Cowen upgraded Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $21.33.

Organon & Co. Price Performance

Shares of NYSE:OGN traded down $0.26 during trading on Friday, reaching $14.63. The company had a trading volume of 2,562,701 shares, compared to its average volume of 2,305,809. The firm's fifty day moving average is $15.37 and its 200 day moving average is $17.69. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The firm has a market capitalization of $3.77 billion, a PE ratio of 2.90, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.